FDA Panel Shoots Down Intellipharma Opioid

A U.S. FDA panel of independent advisers said there was not enough evidence to support the approval of Toronto-based Intellipharmaceutics International's long-acting opioid painkiller, according to a Reuters article.

The painkiller was developed as an abuse-deterrent version of Purdue Pharma's OxyContin, which already has tamper-resistant properties. The drug has a blue dye that is emitted if the tablet is manipulated, which could help identify abusers, and a nasal irritant to discourage misuse, the story said.

Read the full article